| abstract |
The invention relates to crystalline erlotinib and in particular crystalline erlotinib hydrate. The crystalline erlotinib may be comprised in a pharmaceutical preparation. The crystalline erlotinib may be produced by precipitating from a solution that comprises erlotinib dissolved in a solvent wherein said solvent is selected from methanol, ethanol, isopropanol, acetone, acetonitrile, chloroform, 1,4-dioxane, toluene, and mixtures thereof. The crystalline erlotinib may be used for producing erlotinib salts. |